Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

2.4%

4 terminated/withdrawn out of 169 trials

Success Rate

96.9%

+10.4% vs industry average

Late-Stage Pipeline

23%

39 trials in Phase 3/4

Results Transparency

7%

9 of 124 completed trials have results

Key Signals

21 recruiting9 with results

Enrollment Performance

Analytics

Phase 1
78(55.3%)
Phase 3
27(19.1%)
Phase 2
21(14.9%)
Phase 4
12(8.5%)
N/A
2(1.4%)
Early Phase 1
1(0.7%)
141Total
Phase 1(78)
Phase 3(27)
Phase 2(21)
Phase 4(12)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (169)

Showing 20 of 169 trials
NCT07340164Phase 2Recruiting

Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy

Role: collaborator

NCT05788718Completed

An Observational Study to Analyze the Prescription Pattern of Sugammadex and Its Effectiveness and Safety

Role: lead

NCT07516847Phase 2Not Yet Recruiting

Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes

Role: collaborator

NCT07495579Phase 2Not Yet Recruiting

Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)

Role: collaborator

NCT05179889Phase 2Recruiting

Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer

Role: collaborator

NCT07421375Phase 1Not Yet Recruiting

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions

Role: lead

NCT07421401Phase 1Not Yet Recruiting

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions

Role: lead

NCT07421414Phase 1Not Yet Recruiting

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions

Role: lead

NCT07421388Phase 1Not Yet Recruiting

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions

Role: lead

NCT07373613Phase 2Not Yet Recruiting

A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

Role: lead

NCT07180771Phase 2Not Yet Recruiting

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

Role: lead

NCT07263178Recruiting

A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.

Role: lead

NCT07263191Recruiting

A Study of Olanzapine in Participants With Bipolar Disorder.

Role: lead

NCT06165250Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

Role: lead

NCT06021483Recruiting

Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection

Role: lead

NCT05970237Recruiting

A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

Role: lead

NCT06821945Phase 2Recruiting

A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia

Role: lead

NCT06972732Phase 4Recruiting

A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

Role: lead

NCT05559606Completed

An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe

Role: lead

NCT06314919Recruiting

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

Role: lead